Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 9Neoplasms 2Fallopian Tube Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Glioblastoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Temozolomide 39Radiotherapy 18Lomustine 12Bevacizumab 11Carmustine 8Radiation 7Procarbazine 4Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3pembrolizumab 2depatuxizumab mafodotin 2Tf-CRM107 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Drug Therapy 2Dihematoporphyrin Ether 2DNA Methylation 2Carboplatin 2ABT-414 2trans-sodium crocetinate 1tofacitinib 1sargramostim 1rindopepimut 1niraparib 1marizomib 1enzastaurin 1edotecarin 1contrast agent BR1 1cediranib 1carmustine, poliferprosan 20 drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Glioblastoma × niraparib × Clear all
NCT06388733 2026-04-01

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NeuroTrials, LLC

Phase 3 Recruiting
450 enrolled
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡